The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets
Kristoffer Hellstrand, MD, PhD, discusses his group’s aims and ongoing work at Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden, which includes both basic research and the clinical development of agents. Prof. Hellstrand also discusses a recent publication from his group on how HLA-B-21 dimorphism impacts NK-cell function and the clinical outcome of immunotherapy in acute myeloid leukemia (AML).
